Navigation Links
UCI neuroscientists create fiber-optic method of arresting epileptic seizures
Date:1/24/2013

Irvine, Calif., Jan. 24, 2013 UC Irvine neuroscientists have developed a way to stop epileptic seizures with fiber-optic light signals, heralding a novel opportunity to treat the most severe manifestations of the brain disorder.

Using a mouse model of temporal lobe epilepsy, Ivan Soltesz, Chancellor's Professor and chair of anatomy & neurobiology, and colleagues created an EEG-based computer system that activates hair-thin optical strands implanted in the brain when it detects a real-time seizure.

These fibers subsequently "turn on" specially expressed, light-sensitive proteins called opsins, which can either stimulate or inhibit specific neurons in select brain regions during seizures, depending on the type of opsin.

The researchers found that this process was able to arrest ongoing electrical seizure activity and reduce the incidence of severe "tonic-clonic" events.

"This approach is useful for understanding how seizures occur and how they can be stopped experimentally," Soltesz said. "In addition, clinical efforts that affect a minimum number of cells and only at the time of a seizure may someday overcome many of the side effects and limitations of currently available treatment options."

Study results appear online in Nature Communications.

More than 3 million Americans suffer from epilepsy, a condition of recurrent spontaneous seizures that occur unpredictably, often cause changes in consciousness, and can preclude normal activities such as driving and working. In at least 40 percent of patients, seizures cannot be controlled with existing drugs, and even in those whose seizures are well controlled, the treatments can have major cognitive side effects.

Although the study was carried out in mice, not humans, Soltesz said the work could lead to a better alternative to the currently available electrical stimulation devices.


'/>"/>
Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert

Page: 1

Related biology news :

1. Neuroscientists prove ultrasound can be tweaked to stimulate different sensations
2. UT Dallas researchers awarded $4.3 million to create next-generation technologies
3. Researchers create flexible, nanoscale bed of nails for possible drug delivery
4. Study quantifies the size of holes antibacterials create in cell walls to kill bacteria
5. Powerful enzymes create ethanol from agricultural harvest waste
6. Even in same vineyard, different microbes may create variations in wine grapes
7. Protein creates paths for growing nerve cells
8. New geometries: Researchers create new shapes of artificial microcompartments
9. Rice, Texas Childrens team creates biocompatible patch to heal infants with birth defects
10. Conservationists to create blueprint for saving Malaysias elephants
11. Cells from skin create model of blinding eye disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 C-Labs LLC, a leading provider of ... (IoT), today announced the appointment of John Traynor ... a strategic advisor to the firm, Mr. Traynor will ... is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. Photo ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/7/2014)... Debra Auguste, associate professor, biomedical engineering, in the ... of New York, have identified a molecule that ... the most aggressive forms of breast cancer. , ... mortality rate owing to aggressive proliferation and metastasis ... Professor Auguste,s team, discovered the overexpression of intercellular ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... School of Medicine have found that new disease pathways ... 1 Gaucher disease, a rare genetic disorder in which ... liver/spleen enlargement, osteoporosis, bone pain, and increased risk of ... could lead to less expensive and more effective ways ...
... the cure for a fungus and parasite that affects millions ... of Missouri Chemistry Professor John Tanner would be the forensic ... model that could eventually solve the crime. Tanner, who also ... joined forces with Pablo Sobrado, an assistant professor of biochemistry ...
... CHAMPAIGN, Ill. University of Illinois chemists have ... in shoe bombs. It could lead to inexpensive, easy-to-use ... elsewhere. Triacetone triperoxide (TATP) is a high-powered explosive ... bombing attempts. TATP is easy to prepare from readily ...
Cached Biology News:Cheaper, more effective treatment of type 1 Gaucher disease possible 2X-ray diffraction may play key role in stopping 'kissing bug,' fungus 2Sniffing out shoe bombs: A new and simple sensor for explosive chemicals 2
(Date:11/22/2014)... 2014 Respiratory therapy students will ... management of life-like respiratory ailments using the latest ... Grand Rapids-based, Michigan Instruments Inc. developers of the ... the respiratory simulation units to the pro-gram, which ... and Muskegon Community College are collaborating to offer ...
(Date:11/21/2014)... USA (PRWEB) November 19, 2014 The ... our lives was shared with more than 200 primary ... postgraduate students from the University of Otago Physics Department ... . The Otago students, members of the university’s OSA/SPIE ... Zealand in early September, giving children from small, rural ...
(Date:11/21/2014)... NY (PRWEB) November 20, 2014 The ... now available as an open access journal featuring the ... infrared fluorescent proteins to preserve photoresponsiveness in the retina ... Two-color fluorescent in situ hybridization using chromogenic substrates in ... for DNA, RNA, and protein electrophoresis , ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris Group ... dosed in its Phase 1 trial of ADI-PEG ... the treatment of malignant pleural mesothelioma (MPM) and ... conducting clinical trials on ADI-PEG 20, both as ... the treatment of several other indications, including breast ...
Breaking Biology Technology:Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... , June 1 /PRNewswire/ -- Pioneer Surgical Technology, ... follow up on the NuBac IDE feasibility study patients was presented at ... of Spine Surgery (SAS) in New Orleans by Domagoj ... , , ...
... June 1 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... has received approval from the Belgian Federal Agency for ... 3 trial examining REOLYSIN in combination with paclitaxel and ... This is the same trial that was agreed to ...
... BOZEN, Sud-Tirol, Italy , May ... joint venture Health Robotics South East Asia Ltd.,scored two ... to deliver CytoCare-made accurate and sterile,oncology patient doses in ... Health,Robotics, CytoCare is the first and only robot in ...
Cached Biology Technology:Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Health Robotics South East Asia Wins two key Cancer Therapy Outsourcing Projects in Malaysia and Thailand 2Health Robotics South East Asia Wins two key Cancer Therapy Outsourcing Projects in Malaysia and Thailand 3